166 related articles for article (PubMed ID: 23712759)
1. Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity.
Yamniuk AP; Ditto N; Patel M; Dai J; Sejwal P; Stetsko P; Doyle ML
J Pharm Sci; 2013 Aug; 102(8):2424-39. PubMed ID: 23712759
[TBL] [Abstract][Full Text] [Related]
2. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.
Estep P; Caffry I; Yu Y; Sun T; Cao Y; Lynaugh H; Jain T; Vásquez M; Tessier PM; Xu Y
MAbs; 2015; 7(3):553-61. PubMed ID: 25790175
[TBL] [Abstract][Full Text] [Related]
3. Prediction of aggregation prone regions of therapeutic proteins.
Chennamsetty N; Voynov V; Kayser V; Helk B; Trout BL
J Phys Chem B; 2010 May; 114(19):6614-24. PubMed ID: 20411962
[TBL] [Abstract][Full Text] [Related]
4. Aggregation risk prediction for antibodies and its application to biotherapeutic development.
Obrezanova O; Arnell A; de la Cuesta RG; Berthelot ME; Gallagher TR; Zurdo J; Stallwood Y
MAbs; 2015; 7(2):352-63. PubMed ID: 25760769
[TBL] [Abstract][Full Text] [Related]
5. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
[TBL] [Abstract][Full Text] [Related]
7. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity.
Lauer TM; Agrawal NJ; Chennamsetty N; Egodage K; Helk B; Trout BL
J Pharm Sci; 2012 Jan; 101(1):102-15. PubMed ID: 21935950
[TBL] [Abstract][Full Text] [Related]
8. Application of a high-throughput relative chemical stability assay to screen therapeutic protein formulations by assessment of conformational stability and correlation to aggregation propensity.
Rizzo JM; Shi S; Li Y; Semple A; Esposito JJ; Yu S; Richardson D; Antochshuk V; Shameem M
J Pharm Sci; 2015 May; 104(5):1632-40. PubMed ID: 25757872
[TBL] [Abstract][Full Text] [Related]
9. On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution.
Arosio P; Jaquet B; Wu H; Morbidelli M
Biophys Chem; 2012 Jul; 168-169():19-27. PubMed ID: 22750560
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
11. A novel screening method to assess developability of antibody-like molecules.
Kohli N; Jain N; Geddie ML; Razlog M; Xu L; Lugovskoy AA
MAbs; 2015; 7(4):752-8. PubMed ID: 25961854
[TBL] [Abstract][Full Text] [Related]
12. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.
Lavoisier A; Schlaeppi JM
MAbs; 2015; 7(1):77-83. PubMed ID: 25514497
[TBL] [Abstract][Full Text] [Related]
13. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool.
Xu Y; Roach W; Sun T; Jain T; Prinz B; Yu TY; Torrey J; Thomas J; Bobrowicz P; Vásquez M; Wittrup KD; Krauland E
Protein Eng Des Sel; 2013 Oct; 26(10):663-70. PubMed ID: 24046438
[TBL] [Abstract][Full Text] [Related]
14. Solubility and binding properties of PEGylated lysozyme derivatives with increasing molecular weight on hydrophobic-interaction chromatographic resins.
Müller E; Josic D; Schröder T; Moosmann A
J Chromatogr A; 2010 Jul; 1217(28):4696-703. PubMed ID: 20570270
[TBL] [Abstract][Full Text] [Related]
15. Salting out of proteins using ammonium sulfate precipitation.
Duong-Ly KC; Gabelli SB
Methods Enzymol; 2014; 541():85-94. PubMed ID: 24674064
[TBL] [Abstract][Full Text] [Related]
16. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
[TBL] [Abstract][Full Text] [Related]
17. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
[TBL] [Abstract][Full Text] [Related]
18. High-throughput assay for measuring monoclonal antibody self-association and aggregation in serum.
Li X; Geng SB; Chiu ML; Saro D; Tessier PM
Bioconjug Chem; 2015 Mar; 26(3):520-8. PubMed ID: 25714504
[TBL] [Abstract][Full Text] [Related]
19. Engineering aggregation-resistant antibodies.
Perchiacca JM; Tessier PM
Annu Rev Chem Biomol Eng; 2012; 3():263-86. PubMed ID: 22468604
[TBL] [Abstract][Full Text] [Related]
20. Optimization on Fc for Improvement of Stability and Aggregation Resistance.
Chen X; Zeng F; Huang T; Cheng L; Liu H; Gong R
Curr Pharm Biotechnol; 2016; 17(15):1353-1359. PubMed ID: 27855600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
